Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asjsur.2024.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy of plasma exosomal miRNAs as predictive biomarkers for PD-1 blockade plus chemotherapy in gastric cancer.
Transl Cancer Res
November 2024
Department of Public Health, International College, Krirk University, Bangkok, Thailand.
Background: The response of gastric cancer (GC) patients to first-line programmed cell death 1 (PD-1) blockade and S-1 plus oxaliplatin (SOX) chemotherapy varies considerably, and the underlying mechanisms driving this variability remain elusive. Exosomal microRNAs (miRNAs or miRs) have emerged as potential biomarkers for efficacy prediction due to their roles in GC biology and stable expression in serum. In this study, we aimed to identify biomarkers to predict patients' response to anti-PD-1 therapy and further elucidate the potential mechanisms by which these exosomal miRNAs modulate the immune response in GC.
View Article and Find Full Text PDFLong-term outcomes of S-1 and oxaliplatin neoadjuvant chemotherapy with total mesorectal excision and lateral lymph node dissection for rectal cancer.
BMC Gastroenterol
December 2024
Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki-shi, Aomori, 036-8562, Japan.
Purpose: Chemoradiotherapy (CRT) for rectal cancer is limited by its harmful side effects and its insufficient benefit on lateral lymph node metastases. The purpose of this study was to evaluate the long-term outcomes of S-1 and oxaliplatin with total mesorectal excision (TME) and lateral lymph node dissection (LLND) without radiation for rectal cancer.
Methods: The inclusion criteria were patients with stage II or III rectal cancer located within 10 cm from the anal verge.
SOX chemotherapy is effective treatment for gastric cancer with liver metastases.
Asian J Surg
December 2024
Department of General Surgery, The Third People's Hospital of Dalian, Dalian Medical University, Dalian, 116033, China. Electronic address:
Article Synopsis
- A 60s male patient diagnosed with advanced gastric cancer (with pyloric stenosis and enlarged lymph nodes) experienced significant tumor reduction after two courses of chemotherapy before surgery.
- He underwent laparoscopic gastric jejunal bypass followed by distal gastrectomy and para-aortic lymph node dissection, with positive surgical results and no further tumor growth observed.
- After the operation, he received a year of adjuvant chemotherapy and has remained recurrence-free for 1.5 years, highlighting the effectiveness of preoperative treatment for this condition.
Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.
BMJ Open
December 2024
Department of General Surgery & Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Article Synopsis
- * The research is a phase II trial involving 37 patients, aiming to assess various outcomes like tumor response rates and survival rates after receiving a specific chemotherapy regimen along with cadonilimab before surgery.
- * The study has received ethical approval, requires informed consent from participants, and aims to contribute valuable data on the safety and effectiveness of this combined therapy over the course of the trial, which runs until mid-2025.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!